Related Experiment Video

Updated: Nov 15, 2025

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound
10:08

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound

Published on: December 2, 2014

16.3K

TRANSFORMING GROWTH FACTOR AND ARTERIAL STIFFNESS IN PATIENTS WITH UNCONTROLLED ARTERIAL HYPERTENSION

V Podzolkov1, T Safronova1, N Nebieridze1

  • 11I.M. Sechenov First Moscow State Medical University (Sechenov University), 2nd Internal Medicine Department of N.V. Sklifosovsky Institute of Clinical Medicine, Moscow, Russia.

Georgian Medical News
|March 4, 2021
PubMed

Insights

Uncontrolled hypertension is linked to higher levels of TGF-β1 and increased arterial stiffness, indicated by cardio-ankle vascular index (CAVI). These factors correlate with target organ damage in hypertensive patients.

Area of Science:

  • Cardiovascular Medicine
  • Hypertension Research
  • Biomarker Discovery

Background:

  • Arterial stiffness and target organ damage are key complications of hypertension.
  • Transforming growth factor-beta 1 (TGF-β1) is implicated in cardiovascular remodeling.
  • Understanding the interplay between TGF-β1, arterial stiffness, and organ damage is crucial for managing hypertension.

Purpose of the Study:

  • To investigate the relationship between TGF-β1 levels, arterial stiffness (measured by CAVI), and target organ damage in patients with uncontrolled arterial hypertension (UAH).
  • To compare TGF-β1 and CAVI values across UAH, controlled hypertensive (CAH), and healthy control groups.

Main Methods:

  • Cross-sectional study involving 140 hypertensive patients (30 UAH, 80 CAH) and 30 controls.
  • Measurement of serum TGF-β1 levels.
  • Assessment of arterial stiffness using cardio-ankle vascular index (CAVI).
  • Correlation and regression analyses to identify relationships between variables.

Main Results:

  • Patients with UAH exhibited significantly higher TGF-β1 levels and CAVI compared to CAH and control groups (p<0.05).
  • A significant positive correlation was found between TGF-β1 levels and CAVI in hypertensive patients (r=0.777 for CAH, r=0.753 for UAH; p<0.05).
  • TGF-β1 levels were significantly associated with myocardial mass, CAVI, and creatinine in hypertensive patients (p<0.05).

Conclusions:

  • Elevated TGF-β1 and increased arterial stiffness are characteristic of uncontrolled hypertension.
  • TGF-β1 is a potential biomarker linking arterial stiffness and target organ damage in hypertension.
  • These findings highlight the importance of managing TGF-β1 and arterial stiffness to prevent hypertensive complications.

More Related Videos

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy10:35

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy

Published on: October 19, 2016

10.8K
Measuring the Carotid to Femoral Pulse Wave Velocity Cf-PWV to Evaluate Arterial Stiffness05:51

Measuring the Carotid to Femoral Pulse Wave Velocity Cf-PWV to Evaluate Arterial Stiffness

Published on: May 3, 2018

18.0K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.0K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
327
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
111
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
310
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
666